Sitemap

Sitemap

DI Best Impact Award

DI Best Impact Award

Selection Method and Criteria

Selection Method and Criteria for Diabetology International “Best Impact Award“

The 5th DI Best Impact Award 2025

Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro.

Diabetol Int 12, 389-398 (2021)

Awardee: Leona Yamamoto, MD

Past Awardees

2021	Glucose area under the curve during oral glucose tolerance test as an index of glucose intolerance. Diabetol Int 7, 53-58 (2016) Awardee: Kazuhiko Sakaguchi, MD, PhD
2022	Risk factors associated with abnormal cognition in Japanese outpatients with diabetes, hypertension or dyslipidemia. Diabetol Int 6, 268-274 (2015) Awardee: Hiroki Yokoyama, MD, PhD
2023	Behavioral changes in patients with diabetes during the COVID-19 pandemic. Diabetol Int 12, 241–245 (2021) Awardee: Miyako Kishimoto, MD, PhD
2024	The effect of COVID-19 pandemic on the lifestyle and glycemic control in patients with type 1 diabetes: a retrospective cohort study Diabetol Int 13, 85–90 (2022) Awardee: Yukako Hosomi, MD, PhD
2025 NEW!	Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro. Diabetol Int 12, 389-398 (2021) Awardee: Leona Yamamoto, MD

Update: June 2, 2025